In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
